• Follow Us
CDI Labs LogoCDI Labs Company Logo
  • LAB SERVICES
      • Service Platforms
      • OVERVIEW
      • HuProt™ Services
      • VirD™ GPCR Services
      • VirScan® Services*
      • HuScan® Services*
      • MouseScan™ Services*
      • Tech Access ProgramCustom PhIP-Seq Libraries*
      • Autoantibody Profiling Services
      • OVERVIEW
      • Biomarker Discovery
      • Patient Stratification
      • Patient Response / Adverse Reaction Prediction
      • Diagnostic Development
      • Vaccine Development and Safety
      • Viral Exposure Profiling
      • Target ID Services
      • OVERVIEW
      • Protein-Protein Interactions
      • Protein-Nucleic Acid Interactions
      • Target Deconvolution / Target Discovery
      • Antibody Specificity Validation
      • Post-translational Modification Specificity Testing
      • Chemically Induced Proximity (CIP)
      • Disease Areas
      • OVERVIEW
      • Autoimmune Disease
      • Oncology
      • Neurological Disease
      • Infectious Disease
      • Genetic Disease
      • * Provided exclusively by CDI Labs Canada.
  • SPECIALIZED CRO SERVICES
      • Specialized CRO Services
      • OVERVIEW
      • Antibody Development
      • Antibody Pairs
      • Protein Production
      • Cell Therapy Immunogenicity Testing
      • CRISPR-Cas9 Immunogenicity Testing
      • Post-translational Modification Specificity Profiling
      • Diagnostic Development
  • PROTEOMICS TECHNOLOGIES
      • HuProt™ MicroarrayContains 21,000+ Full-length Human Proteins
      • VirD™ GPCR ProteinsContains291 Non-odorant GPCRs
      • VirScan® PhIP-Seq*Detect antibodies against 68,000+ Viral Protein Sequences
      • HuScan® PhIP-Seq*Detect antibodies against 48,921 Human Proteins and Isoforms
      • MouseScan™ PhIP-Seq* Detect antibodies against 50,135 Murine Proteins and Isoforms
      • * Provided exclusively by CDI Labs Canada.
  • BIOINFORMATICS
      • Bioinformatics
      • OVERVIEW
  • RESOURCES
      • Resources
      • Library Content
      • Publications
      • Videos and Webinars
      • FAQs
  • NEWS  &  EVENTS
      • Blogs
      • Events
      • News
  • COMPANY
      • About Us
      • Leadership
      • Meet CDI Labs
      • Tech Access ProgramCustom PhIP-Seq Libraries*
      • Customer Testimonials
      • Contact Us
      • Sign-up for Our eNews
      • Privacy Policy
  • CONTACT US

You are now leaving the CDI Labs U.S. website and will be directed to the CDI Labs Canada website.

< Older Newer >
Download PDF
  • Share

Wednesday, Sep 23 2020

CDI Labs HuProt™ Protein Arrays Instrumental in Recent Study of Multisystem Inflammatory Syndrome in Children (MIS-C)

Proteomics company CDI Laboratories products used in important study of MIS-C and its relationship to SARS-CoV-2 (COVID-19) infection.

MAYAGUEZ, Puerto Rico and BALTIMORE, Sept. 23, 2020 - CDI Laboratories, Inc. HuProt™ protein microarray provided important data on a recent high impact paper comparing the immune profiles of MIS-C, healthy children and individuals with COVID-19.


(see https://www.newswise.com/coronavirus/mount-sinai-researchers-study-sars-cov2-caussed-mis-c)


In recent months some children that have been infected with SARS-CoV-2 (COVID-19) have developed an inflammatory problem that was initially recognized as very similar in presentation to Kawasaki disease (KD), an acute systemic vasculitis.


A recent paper has mapped the cellular and serological immune dysfunction underlying this novel pediatric inflammatory syndrome associated with SARS-CoV-2, and helped define how this unique disease differs from Kawasaki disease..


Mapping Systemic Inflammation and Antibody Responses in Multisystem

Inflammatory Syndrome in Children (MIS-C)

Conor Gruber, et al.

PII: S0092-8674(20)31231-9

DOI: https://doi.org/10.1016/j.cell.2020.09.034

Reference: CELL 11634


In the above paper auto-antigen reactivity of MIS-C plasma was assayed with CDI Laboratories HuProt protein arrays which contain 81% of the human proteome. This work revealed both known autoimmune-associated autoantibodies (anti-La) and novel candidates that recognize endothelial, gastrointestinal and immune-cell antigens unique to organs affected by MIS-C.


"CDI is very proud that our HuProt array was so useful in looking into this perplexing side effect of COVID-19 infection in children," said Scott Paschke, CDI VP. "Furthermore, PhIP-Seq technology was also used to look at linear epitopes of auto-antibodies, which is another technology that CDI has recently added."



About CDI – CDI is a privately-owned biotechnology corporation, that focuses on contract research services to enable R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. The Company exports products and offers services worldwide and is rapidly expanding its client base and its academic and industrial collaborations.

For more information, visit https://cdi.bio/ or https://cdi.bio/antygen.



Media Contact:

Scott Paschke, VP

CDI Laboratories Inc

518-534-2881 (direct)

[email protected]

  • CDI LABSLinkedin Feed
CDI Labs Footer LogoCDI Labs Company Footer Logo

Become part of the CDI Labs community

Sign up to receive emails on our latest news and updates.

Your First Name
Your Last Name
Your Work Email

Please enter ONLY your work email address.

Sign Up Submit Button

PLATFORMS

  • HuProt™ Proteome Microarray
  • VirD™ GPCR Protein Microarray
  • VirScan® Viral PhIP-Seq*
  • HuScan® Human PhIP-Seq*
  • MouseScan™ Murine PhIP-Seq*
  • * Provided exclusively by CDI Labs Canada.

SERVICES

  • HuProt™ Services
  • VirD™ GPCR Services
  • VirScan® Services*
  • HuScan® Services*
  • MouseScan™ Services*
  • Antibody Development
  • Autoantibody Profiling Overview
  • Target ID Overview
  • Disease Areas Overview
  • Specialized CRO Overview
  • Bioinformatics Overview
  • * Provided exclusively by CDI Labs Canada.

COMPANY

  • Resources
  • Library Content
  • Publications
  • FAQs
  • Videos and Webinars
  • Blogs
  • Events
  • News
  • Sign-up for Our eNews
  • About Us
  • Leadership

CONTACT

  • Email: [email protected]
  • Tel: +1 844-539-6296
  • CONTACT US
  • General Inquiries
  • [email protected]
  • Tel: +1 510 858-2855
  • Technical Support
  • [email protected]
  • Tel: +1 844 539-6296
  • Mailing Address
  • PO. Box 569
  • Mayagüez. PR 00681-0569
  • USA
  • CDI Labs - Mayagüez
  • 12 W Mendez Vigo Avenue
  • 2nd Floor
  • Mayagüez, PR 00680
  • USA
  • Tel: +1 939-280-5293
  • DIRECTIONS
  • CDI Labs - Baltimore
  • 1 N. Haven Street
  • Suite B001
  • Baltimore, MD 21224
  • USA
  • Tel: +1 844-539-6296
  • DIRECTIONS
  • CDI Labs Canada - Toronto
  • MaRS Centre - West Tower
  • 661 University Ave
  • Suite 1300
  • Toronto, ON
  • CANADA M5G 0B7
  • Tel: +1 647-243-5289
  • DIRECTIONS
  • Follow Us

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

© 2025 CDI Labs. All rights reserved.

  • Privacy Policy
  • |
  • Cookie Policy
  • |
  • Terms of Use - Web
  • |
  • Terms & Conditions - Sales
  • |
  • Terms & Conditions - Services